Mycenax Biotech Inc. (TPEX: 4726)

Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	462.03	519.27	1,323	286.93	291.14	193.67
Short-Term Investments	17.04	148.42	16.12	-	-	83.56
Cash & Short-Term Investments	479.06	667.69	1,339	286.93	291.14	277.23
Cash Growth	-47.42%	-50.15%	366.84%	-1.45%	5.02%	-2.09%
Accounts Receivable	118.61	58.53	81.32	320.84	169.03	126.38
Other Receivables	5.5	4.69	3.09	11.33	5.51	1.83
Receivables	124.11	63.22	84.41	332.17	174.54	128.21
Inventory	99.64	112.33	246.72	173.3	84.85	56.12
Prepaid Expenses	85.59	83.25	103.22	89.28	23.82	24.24
Other Current Assets	197.42	171.53	149.95	15.73	2.16	9.15
Total Current Assets	985.82	1,098	1,924	897.41	576.51	494.96
Property, Plant & Equipment	1,779	1,847	1,978	1,351	786.73	592.84
Long-Term Investments	184.72	190.81	199.51	109.59	191.81	149.31
Goodwill	23.92	23.92	23.92	23.92	23.92	23.92
Other Intangible Assets	16.21	18.98	25.93	33.71	36.72	50.93
Long-Term Deferred Tax Assets	95.76	95.49	89.72	81.11	83.45	79.71
Other Long-Term Assets	545.37	495.85	211.93	642.46	53.41	16.33
Total Assets	3,631	3,770	4,453	3,139	1,753	1,408
Accounts Payable	70.73	44.05	52.52	54.68	40.31	24.7
Accrued Expenses	69.15	104.88	104.21	96.4	66.6	51.22
Short-Term Debt	-	-	100	50	100	-
Current Portion of Long-Term Debt	122.16	125.92	105.88	15.6	-	-
Current Portion of Leases	33.84	30.57	37.28	28.59	24.33	13.62
Current Income Taxes Payable	-	-	-	-	0.65	-
Current Unearned Revenue	252.46	187.28	142.28	152.12	125.9	91.69
Other Current Liabilities	90.03	260.72	92.57	142.69	66.99	50.69
Total Current Liabilities	638.37	753.42	634.73	540.07	424.78	231.92
Long-Term Debt	706.88	530.4	656.32	474.4	-	-
Long-Term Leases	57.7	39.39	56.37	176.06	72.28	33.18
Long-Term Deferred Tax Liabilities	-	-	-	3.75	6.68	3.81
Other Long-Term Liabilities	-	-	-	38.07	37.14	37.14
Total Liabilities	1,403	1,323	1,347	1,232	540.89	306.04
Common Stock	2,058	2,059	2,053	1,533	1,282	1,280
Additional Paid-In Capital	401.08	1,074	1,468	576.95	53.11	260.91
Retained Earnings	-237.23	-682.64	-406.83	-254.34	-207.23	-473.31
Comprehensive Income & Other	5.85	-3.32	-8.8	50.72	83.41	34.81
Shareholders' Equity	2,228	2,447	3,106	1,907	1,212	1,102
Total Liabilities & Equity	3,631	3,770	4,453	3,139	1,753	1,408
Total Debt	920.58	726.28	955.85	744.64	196.61	46.8
Net Cash (Debt)	-441.51	-58.59	383.63	-457.72	94.53	230.43
Net Cash Growth	-	-	-	-	-58.98%	-18.62%
Net Cash Per Share	-2.15	-0.29	2.32	-3.08	0.73	1.83
Filing Date Shares Outstanding	205.82	205.89	205.31	153.33	128.24	127.96
Total Common Shares Outstanding	205.82	205.89	205.31	153.33	128.24	127.96
Working Capital	347.45	344.59	1,289	357.34	151.73	263.04
Book Value Per Share	10.82	11.89	15.13	12.43	9.45	8.61
Tangible Book Value	2,188	2,404	3,056	1,849	1,151	1,027
Tangible Book Value Per Share	10.63	11.68	14.88	12.06	8.98	8.03
Buildings	792.86	792.86	791.68	-	-	-
Machinery	1,601	1,603	1,575	837.57	688.02	573.33
Construction In Progress	143.7	106.85	3.35	624.35	260.37	164.56
Leasehold Improvements	317.34	317.34	307.77	276.23	246.21	236.3

Source: S&P Capital IQ. Standard template. Financial Sources.